UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 08, 2023

LifeStance Health Group, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation) 001-40478 (Commission File Number) 86-1832801 (IRS Employer Identification No.)

4800 N. Scottsdale Road Suite 2300 Scottsdale, Arizona (Address of Principal Executive Offices)

85251 (Zip Code)

Registrant's Telephone Number, Including Area Code: 602 767-2100

4800 N. Scottsdale Road, Suite 6000 Scottsdale, Arizona 85251 (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	Written communications pursuant to Rule 425 under the Securi	ties Act (17 CFR 230.425)								
	Soliciting material pursuant to Rule 14a-12 under the Exchange	e Act (17 CFR 240.14a-12)								
	Pre-commencement communications pursuant to Rule 14d-2(b)) under the Exchange Act (17 CF)	R 240.14d-2(b))							
	Pre-commencement communications pursuant to Rule 13e-4(c)	under the Exchange Act (17 CFI	R 240.13e-4(c))							
Securities registered pursuant to Section 12(b) of the Act:										
	Trading									
	Title of each class	Symbol(s)	Name of each exchange on which registered							
	Common Stock, par value \$0.01 per share	Title of each class Symbol(s) Name of each exchange on which registered								
	icate by check mark whether the registrant is an emerging growth Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).	ı company as defined in Rule 405	of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of							
Em	erging growth company $oxtimes$									
	n emerging growth company, indicate by check mark if the regist ounting standards provided pursuant to Section 13(a) of the Exch		tended transition period for complying with any new or revised financial							

Item 2.02 Results of Operations and Financial Condition.

On November 8, 2023, LifeStance Health Group, Inc. ("LifeStance Health Group", "LifeStance" or the "Company") issued a press release announcing its results of operations for the third quarter ended September 30, 2023. A copy of the press release is furnished as Exhibit 99.1.

The information furnished under Item 2.02 of this Current Report on Form 8-K, including the exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference into LifeStance Health Group's filings with the SEC under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 7.01 Regulation FD Disclosure.

A slide presentation, which includes supplemental information related to LifeStance Health Group, is furnished as Exhibit 99.2. The information furnished under Item 7.01 of this Current Report on Form 8-K, including the exhibit, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference into LifeStance Health Group's filings with the SEC under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit	Description
99.1	Press Release dated November 8, 2023.
99.2	Slide presentation providing supplemental information.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto d	luly
authorized.	

LifeStance Health Group, Inc.

Date: November 8, 2023 By: /s/ David Bourdon

David Bourdon

David Bourdon
Chief Financial Officer and Treasurer
(principal financial and accounting officer)

Investor Relations Contact

Monica Prokocki VP of Investor Relations 602-767-2100 investor.relations@lifestance.com

LifeStance Reports Third Quarter 2023 Results

SCOTTSDALE, Ariz. – November 8, 2023 – LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial results for the third quarter ended September 30, 2023.

(All results compared to prior-year comparative period, unless otherwise noted)

Q3 2023 Highlights and FY 2023 Outlook

- Total revenue of \$262.9 million increased \$45.3 million or 21% compared to total revenue of \$217.6 million
- Total clinicians of 6,418 up 18%, a sequential net increase of 286 in the third quarter
- Net loss of \$61.6 million compared to net loss of \$37.9 million, primarily driven by the preliminarily approved settlement of our shareholder class action lawsuit and stock-based compensation expenses
- Adjusted EBITDA of \$14.6 million compared to Adjusted EBITDA of \$15.4 million
- Raising the midpoints of Revenue, Center Margin, and Adjusted EBITDA guidance ranges: Now expecting full year 2023 revenue of \$1.03 to \$1.04 billion, Center Margin of \$292 to \$300 million and Adjusted EBITDA of \$56 to \$60 million

"We delivered another strong quarter," said Ken Burdick, Chairman and CEO of LifeStance. "In addition to solid financial results, we continued to attract high-quality clinical talent with a record quarter of organic recruiting, growing the team by nearly 300 clinicians. As we approach the end of the year, we will continue our commitment to improving the patient and clinician experience while continuing to fortify the company's foundation to build long-term, scalable operations."

Financial Highlights

	Q3 2023	(Q3 2022	Y/Y
(in millions)				
Total revenue	\$ 262.9	\$	217.6	21 %
Loss from operations	(74.4)		(38.8)	92 %
Center Margin	76.2		60.3	26%
Net loss	(61.6)		(37.9)	63 %
Adjusted EBITDA	14.6		15.4	(5%)
As % of Total revenue:				
Loss from operations	(28.3 %)		(17.8%)	
Center Margin	29.0%		27.7%	
Net loss	(23.4%)		(17.4%)	
Adjusted EBITDA	5.6%		7.1 %	

(All results compared to prior-year period, unless otherwise noted)

- Total revenue grew 21% to \$262.9 million. Strong revenue growth in the third quarter was driven primarily by net clinician growth and increased visit volumes.
- Loss from operations was \$74.4 million, primarily driven by stock-based compensation expense of \$21.5 million and the preliminarily approved settlement of our shareholder class action lawsuit. Net loss was \$61.6 million.
- Center Margin grew 26% to \$76.2 million, or 29% of total revenue.
- Adjusted EBITDA declined 5% to \$14.6 million, or 5.6% of total revenue. Adjusted EBITDA as a percentage of revenue decreased as a result of higher G&A expenses from investments in the business.

Balance Sheet, Cash Flow and Capital Allocation

For the nine months ended September 30, 2023, LifeStance used \$33.7 million cash flow from operations, including \$25.4 million during the third quarter of 2023. The Company ended the third quarter with cash of \$42.6 million and net long-term debt of \$248.4 million.

2023 Guidance

LifeStance is raising the midpoints of full year Revenue, Center Margin, and Adjusted EBITDA guidance ranges, with the following outlook for 2023:

- The Company expects full year revenue of \$1.03 to \$1.04 billion, Center Margin of \$292 to \$300 million, and Adjusted EBITDA of \$56 to \$60 million.
- For the fourth quarter of 2023, the Company expects total revenue of \$255 to \$265 million, Center Margin of \$73 to \$81 million, and Adjusted EBITDA of \$17 to \$21 million.

Conference Call, Webcast Information, and Presentations

LifeStance will hold a conference call today, November 8, 2023, at 8:30 a.m. Eastern Time to discuss the third quarter 2023 results. Investors who wish to participate in the call should dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, approximately 10 minutes before the call begins and provide conference ID number 3827662 or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentations section of the LifeStance Investor Relations website (https://investor.lifestance.com), where related materials will be posted prior to the conference call.

About LifeStance Health Group, Inc.

Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation's largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable, and personalized mental healthcare. LifeStance employs approximately 6,400 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and approximately 600 centers. To learn more, please visit www.LifeStance.com.

We routinely post information that may be important to investors on the "Investor Relations" section of our website at investor.lifestance.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Forward-Looking Statements

Statements in this press release and on the related teleconference that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. These statements include, but are not limited to, statements with respect to: full year and fourth quarter guidance and management's related assumptions; the Company's financial position; business plans and objectives; operating results; working capital and liquidity; and other statements contained in this press release that are not historical facts. When used in this press release and on the related teleconference, words such as "may," "will," "should," "could," "intend," "potential," "continue," "anticipate," "believe," "estimate," "expect," "plan," "target," "predict," "project," "seek" and similar expressions as they relate to us are intended to identify forward-looking statements. They involve a number of risks and uncertainties that may cause actual events and results to differ materially from such forward-looking statements. These risks and uncertainties include, but are not limited to: we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our ability to recruit new clinicians and retain existing clinicians; if reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be harmed; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with affiliated practices, which we do not own, to provide health care services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; we operate in a competitive industry, and if we are not able to compete effectively, our business, results of operations and financial condition would be harmed; the impact of health care reform legislation and other changes in the healthcare industry and in health care spending on us is currently unknown, but may harm our business; if our or our vendors' security measures fail or are breached and unauthorized access to our employees', patients' or partners' data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; actual or anticipated changes or fluctuations in our results of operations; our existing indebtedness could adversely affect our business and growth prospects; and other risks and uncertainties set forth under "Risk Factors" included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent filings

made with the Securities and Exchange Commission. LifeStance does not undertake to update any forward-looking statements made in this press release to reflect any change in management's expectations or any change in the assumptions or circumstances on which such statements are based, except as otherwise required by law.

Non-GAAP Financial Information

This press release contains certain non-GAAP financial measures, including Center Margin, Adjusted EBITDA, and Adjusted EBITDA margin. Tables showing the reconciliation of these non-GAAP financial measures to the comparable GAAP measures are included at the end of this release. Management believes these non-GAAP financial measures are useful in evaluating the Company's operating performance, and may be helpful to securities analysts, institutional investors and other interested parties in understanding the Company's operating performance and prospects. These non-GAAP financial measures, as calculated, may not be comparable to companies in other industries or within the same industry with similarly titled measures of performance. Therefore, the Company's non-GAAP financial measures should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP, such as net loss or loss from operations.

Center Margin and Adjusted EBITDA anticipated for the fourth quarter of 2023 and full year 2023 are calculated in a manner consistent with the historical presentation of these measures at the end of this release. Reconciliation for the forward-looking fourth quarter of 2023 and full year 2023 Center Margin and Adjusted EBITDA guidance is not being provided, as LifeStance does not currently have sufficient data to accurately estimate the variables and individual adjustments for such reconciliation. As such, LifeStance management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results.

Management acknowledges that there are many items that impact a company's reported results and the adjustments reflected in these non-GAAP measures are not intended to present all items that may have impacted these results.

####

Consolidated Financial Information and Reconciliations

CONSOLIDATED BALANCE SHEETS (unaudited)

(In thousands, except for par value)

	Septe	mber 30, 2023	Dece	mber 31, 2022
CURRENT ASSETS				
Cash and cash equivalents	\$	42,605	\$	108,621
Patient accounts receivable, net		149,716		100,868
Prepaid expenses and other current assets		71,929		23,734
Total current assets		264,250		233,223
NONCURRENT ASSETS				
Property and equipment, net		190,067		194,189
Right-of-use assets		180,685		199,431
Intangible assets, net		233,615		263,294
Goodwill		1,293,426		1,272,939
Other noncurrent assets		13,023		10,795
Total noncurrent assets		1,910,816		1,940,648
Total assets	\$	2,175,066	\$	2,173,871
LIABILITIES AND STOCKHOLDERS' EQUITY			-	
CURRENT LIABILITIES				
Accounts payable	\$	10,400	\$	12,285
Accrued payroll expenses		83,618		75,650
Other accrued expenses		91,030		30,428
Current portion of contingent consideration		8,964		15,876
Operating lease liabilities, current		43,604		38,824
Other current liabilities		3,258		2,936
Total current liabilities		240,874	_	175,999
NONCURRENT LIABILITIES		•		•
Long-term debt, net		248,371		225,079
Operating lease liabilities, noncurrent		191,515		212,586
Deferred tax liability, net		38,403		38,701
Other noncurrent liabilities		855		2,783
Total noncurrent liabilities		479,144	_	479,149
Total liabilities	\$	720,018	\$	655,148
COMMITMENTS AND CONTINGENCIES	*	,	-	333,213
STOCKHOLDERS' EQUITY				
Preferred stock – par value \$0.01 per share; 25,000 shares authorized as of September 30, 2023 and December 31, 2022; 0 shares issued and outstanding as of September 30, 2023 and December 31, 2022		_		_
Common stock – par value \$0.01 per share; 800,000 shares authorized as of September 30, 2023 and December 31, 2022; 378,607 and 375,964 shares issued and outstanding as of September 30, 2023 and December 31, 2022,		2.50		0.704
respectively		3,788		3,761
Additional paid-in capital		2,162,766		2,084,324
Accumulated other comprehensive income		4,381		3,274
Accumulated deficit		(715,887)		(572,636)
Total stockholders' equity		1,455,048		1,518,723
Total liabilities and stockholders' equity	\$	2,175,066	\$	2,173,871

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited)

(In thousands, except for Net Loss per Share)

	Three Months Ended September 30,					Nine Months Ended September 30,			
		2023		2022		2023		2022	
TOTAL REVENUE	\$	262,895	\$	217,560	\$	775,062	\$	630,182	
OPERATING EXPENSES									
Center costs, excluding depreciation and amortization shown separately below		186,686		157,267		556,280		455,857	
General and administrative expenses		130,945		81,248		317,425		288,176	
Depreciation and amortization		19,621		17,884		58,220		50,311	
Total operating expenses	\$	337,252	\$	256,399	\$	931,925	\$	794,344	
LOSS FROM OPERATIONS	\$	(74,357)	\$	(38,839)	\$	(156,863)	\$	(164,162)	
OTHER INCOME (EXPENSE)		(, ,		,		, ,		, ,	
Gain on remeasurement of contingent consideration		1,867		1,176		4,443		562	
Transaction costs		_		(210)		(89)		(507)	
Interest expense, net		(5,477)		(4,189)		(15,688)		(14,763)	
Other expense		(1)		(144)		(70)		(144)	
Total other expense	\$	(3,611)	\$	(3,367)	\$	(11,404)	\$	(14,852)	
LOSS BEFORE INCOME TAXES		(77,968)		(42,206)		(168,267)		(179,014)	
INCOME TAX BENEFIT		16,385		4,353		26,964		10,106	
NET LOSS	\$	(61,583)	\$	(37,853)	\$	(141,303)	\$	(168,908)	
NET LOSS PER SHARE, BASIC AND DILUTED		(0.17)		(0.11)		(0.39)		(0.48)	
Weighted-average shares used to compute basic and diluted net loss per share		372,476		357,520		365,556		354,057	
NET LOSS	\$	(61,583)	\$	(37,853)	\$	(141,303)	\$	(168,908)	
OTHER COMPREHENSIVE INCOME		, ,		, , ,		· · · ·		, ,	
Unrealized gains on cash flow hedge, net of tax		230		3,185		1,107		3,185	
COMPREHENSIVE LOSS	\$	(61,353)	\$	(34,668)	\$	(140,196)	\$	(165,723)	

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

(În thousands)

	Nine Months End	ed Sente	mber 30.
	 2023	eu ocpte	2022
CASH FLOWS FROM OPERATING ACTIVITIES	 		
Net loss	\$ (141,303)	\$	(168,908)
Adjustments to reconcile net loss to net cash (used in) provided by operating			
activities:			
Depreciation and amortization	58,220		50,311
Non-cash operating lease costs	30,225		_
Stock-based compensation	78,469		152,235
Loss on debt extinguishment	_		3,380
Amortization of discount and debt issue costs	1,592		1,351
Gain on remeasurement of contingent consideration	(4,443)		(562)
Other, net	5,105		144
Change in operating assets and liabilities, net of businesses acquired:			
Patient accounts receivable, net	(48,484)		(34,606)
Prepaid expenses and other current assets	(52,293)		(5,811)
Accounts payable	(3,848)		1,109
Accrued payroll expenses	7,622		(588)
Operating lease liabilities	(30,109)		_
Other accrued expenses	 65,568		18,816
Net cash (used in) provided by operating activities	\$ (33,679)	\$	16,871
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchases of property and equipment	(29,106)		(68,871)
Acquisitions of businesses, net of cash acquired	(19,820)		(40,294)
Net cash used in investing activities	\$ (48,926)	\$	(109,165)
CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds from long-term debt, net of discount	25,000		237,474
Payments of debt issue costs	(188)		(7,266)
Payments of long-term debt	(1,821)		(181,230)
Prepayment for debt paydown	_		(1,609)
Payments of contingent consideration	(6,402)		(12,290)
Taxes related to net share settlement of equity awards	_		(478)
Net cash provided by financing activities	\$ 16,589	\$	34,601

(66,016)

108,621

42,605

15,424

416

1,985

5,303

\$

\$

\$

\$

\$

\$

\$

\$

\$

\$

(57,693)

148,029

90,336

9,518

1,780

264

7,719

8,607

Net cash provided by financing activities
NET DECREASE IN CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTS – END OF PERIOD

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

SUPPLEMENTAL DISCLOSURES OF NON CASH INVESTING AND

Contingent consideration incurred in acquisitions of businesses

Acquisition of property and equipment included in liabilities

Cash and Cash Equivalents - Beginning of period

Equipment financed through finance leases

Cash paid for interest, net Cash paid for taxes, net of refunds

FINANCING ACTIVITIES

RECONCILIATION OF LOSS FROM OPERATIONS TO CENTER MARGIN (unaudited)

	Three Months End	led Sep	otember 30,	Nine Months Ended September 30,			
	 2023		2022		2023		2022
(in thousands)							
Loss from operations	\$ (74,357)	\$	(38,839)	\$	(156,863)	\$	(164,162)
Adjusted for:							
Depreciation and amortization	19,621		17,884		58,220		50,311
General and administrative expenses (1)	130,945		81,248		317,425		288,176
Center Margin	\$ 76,209	\$	60,293	\$	218,782	\$	174,325

⁽¹⁾ Represents salaries, wages and employ based compensation for all employees. and employee benefits for our executive leadership, finance, human resources, marketing, billing and credentialing support and technology infrastructure and stock-

RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA (unaudited)

	Three Months End	tember 30,	Nine Months Ended September 30,			
	 2023		2022	 2023		2022
(in thousands)						
Net loss	\$ (61,583)	\$	(37,853)	\$ (141,303)	\$	(168,908)
Adjusted for:						
Interest expense, net	5,477		4,189	15,688		14,763
Depreciation and amortization	19,621		17,884	58,220		50,311
Income tax benefit	(16,385)		(4,353)	(26,964)		(10,106)
Gain on remeasurement of contingent						
consideration	(1,867)		(1,176)	(4,443)		(562)
Stock-based compensation expense	21,525		34,870	78,469		152,235
Loss on disposal of assets	1		144	70		144
Transaction costs (1)	_		210	89		507
Executive transition costs	114		494	636		494
Litigation costs (2)	45,418		104	49,267		104
Strategic initiatives (3)	790		_	3,242		_
Real estate optimization and						
restructuring charges (4)	1,257		_	4,977		_
Other expenses ⁽⁵⁾	214		866	803		3,511
Adjusted EBITDA	\$ 14,582	\$	15,379	\$ 38,751	\$	42,493

- Primarily includes capital markets advisory, consulting, accounting and legal expenses related to our acquisitions.

 Litigation costs include only those costs which are considered non-recurring and outside of the ordinary course of business based on the following considerations, which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) the complexity of the case (e.g., complex class action litigation), (iii) the nature of the remedy(ies) sought, including the size of any monetary damages sought, (iv) the counterparty involved, and (v) our overall litigation strategy. During the three and nine months ended September 30, 2023, litigation costs included cash expenses related to three distinct litigation matters, including (x) a securities class action litigation.

 Strategic initiatives consist of expenses directly related to a multi-phase system upgrade in connection with our recent and significant expansion. During each of the three and nine months ended September 30, 2023, we continued a process of evaluating and adopting three critical enterprise-wide systems for (i) human resources management, (ii) clinician credentialing and onboarding process and (iii) a scalable electronic health resources system. Strategic initiatives represents costs, such as third-party consulting costs and one-time costs, that are not part of our ongoing operations related to these enterprise-wide systems. We considered the frequency and scale of this multi-part enterprise upgrade when determining that the expenses were not normal, recurring operating expenses. (3) recurring operating expenses
- recurring operating expenses.
 Real estate optimization and restructuring charges consist of cash expenses and non-cash charges related to our real estate optimization initiative, which include certain asset impairment and disposal costs, certain gains and losses related to early lease terminations, and exit and disposal costs related to our real estate optimization initiative to consolidate our physical footprint. As the decision to close these centers was part of a significant strategic project driven by a historic shift in behavior, the magnitude of center closures has been and is expected to be greater than what would be expected as part of ordinary business operations and do not constitute normal recurring operating activities.

 Primarily includes costs incurred to consummate or integrate acquired centers, certain of which are wholly-owned and certain of which are affiliated practices, in addition to the compensation paid to former owners of acquired centers and related expenses that are not reflective of the ongoing operating expenses of our centers. Acquired center integration and other are components of general and administrative expenses included in our unaudited consolidated statements of operations and comprehensive loss. Former owner fees is a component of center costs, excluding depreciation and amortization included in our unaudited consolidated statements of operations and comprehensive loss. (4)
- (5)



Reimagining Mental Health

Q3 2023 Earnings Presentation • November 8, 2023



Forward-Looking Statements

Cautionary Note Regarding Forward-Looking Statements
This presentation and related oral statements, including during any question and answer portion of the presentation, contain forward-looking statements about LifeStance Health Group, Inc. and its subsidiaries ("LifeStance") and the industry in which This presentation and related oral statements, including during any question and answer portion of the presentation, contain forward-looking statements about LifeStance paperates, including statements regarding; citull-year and fourth-quarter guidance and management's related assumptions; the Company's financial position; business plans and objectives; including capital allocation, operating results; working capital allocation; business plans and objectives; including capital allocation; operating results; working capital allocation; business position; business plans and objectives; including capital allocation; operating results; working capital allocation; business strategy, and prospects. LifeStance's control and which are largely based on our current expectations and projections about future events and financial trends that we believe may affect LifeStance's financial condition, results of operations, business strategy, and prospects. LifeStance's actual results, events, or circumstance may differ materially from these statements. Forward-looking statements include all statements that facts. Words such as "anticipate," "believe," "envision," "envision, "envision, envision, en patients, our business could be harmed; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with affiliated practices, which we do not own, to provide health care services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; we operate in a competitive industry, and if we are not able to compete effectively, our business, results of operations and financial condition would be harmed; the impact of health care reform legislation and other changes in the health care spending on us is currently unknown, but may harm our business; if our or our vendors' security measures fail or are breached and unauthorized access to our employees', patients' or partners' data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; actual or anticipated changes or fluctuations in our results of operations, our existing indebtedness could adversely affect our business and growth prospects; and the other

factors set forth in our fillings with the Securities and Exchange Commission.

The forward-looking statements, together with statements relating to our past performance, should not be regarded as a reliable indicator of our future performance. We undertake no obligation to update any forward-looking statements made in this presentation to reflect events or circumstances after the date of this presentation or to reflect new information or the occurrence of unanticipated events, except as may be required by law. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future mergers, dispositions, joint

In addition to financial measures presented in accordance with U.S. generally accepted accounting principles ("GAAP"), this presentation includes certain non-GAAP financial measures, including Center Margin, Adjusted EBITDA, Adjusted EBITDA Margin and Free Cash Flow. These non-GAAP measures are in addition to, and not a substitute for, or superior to, measures of financial performance prepared in accordance with U.S. GAAP. The non-GAAP financial measures used by LifeStance may differ from the non-GAAP financial measures used by other companies. A reconciliation of these measures to the most directly comparable U.S. GAAP measure is included in the Appendix to these slides or as otherwise described in these slides.

This presentation also contains information regarding our market and industry that is derived from third-party research and publications. This information involves a number of assumptions and limitations. Forecasts, assumptions, expectations, beliefs, estimates and projections involve risk and uncertainties and are subject to change based on various factors



LifeStance: Reimagining Mental Healthcare

OUR MISSION Increasing access to trusted, affordable, and personalized mental healthcare

OUR VISION A truly healthy society where mental and physical healthcare are unified to make lives better

Building the Leading Outpatient Mental Health Platform











National platform with unmatched scale

Multidisciplinary clinician model composed of W-2 employed psychiatrists, APNs, psychologists & therapists Tech-enabled platform supporting hybrid model of virtual and in-person care In-network reimbursement providing affordable access to high-quality care



Note: Unless otherwise stated, data is as of September 30, 2023; ⁽¹⁾ Trailing twelve months




Q3 2023 Highlights

- Q3 Revenue of \$262.9 million increased 21% year-over-year
- Total clinicians of 6,418, +18% Y/Y; 286 net clinician adds in Q3
- Q3 Center Margin of \$76.2 million, or 29.0% as a percentage of revenue
- Q3 Adjusted EBITDA of \$14.6 million, or 5.6% as a percentage of revenue
- Ended Q3 with a cash position of \$42.6 million

Note: See reconciliation of GAAP to non-GAAP measures in the Appendix to this presentation



Q3 2023 Results





Quarterly Trends









Note: See reconciliation of GAAP to non-GAAP measures in the Appendix to this presentation. Amounts are unaudited.



Balance Sheet, Cash Flow, and Capital Allocation

Balance Sheet & Cash Flow

\$43M \$248M Cash & Cash Equivalents Net Long-term Debt* (\$34M) \$29M Operating Cash Flow (YTD) Capital Expenditures (YTD)

Capital Allocation



De Novos

Selective deployment to enable clinician and market growth

Opened 8 de novos in Q3 and 23 YTD



Acquisitions

No acquisitions in Q3 No further M&A anticipated in 2023

Evolving from purely growth mindset to balanced set of objectives that include operational excellence, profitable growth, and disciplined capital deployment

*Long-Term Debt is Net of Current Portion and Unamortized Discount and Debt Issue Costs



2023 Guidance

(All \$ in M)	FY 2023	Q4 2023
Revenue	\$1,030 — \$1,040 (Narrowed from \$1,010 - \$1,040; midpoint raised)	\$255 – \$265
Center Margin	\$292 — \$300 (Narrowed from \$280 - \$300; midpoint raised)	\$73 – \$81
Adj. EBITDA	\$56 — \$60 (Narrowed from \$50 - \$62; midpoint raised)	\$17 – \$21

Planning Assumptions

- Assumes no more than 36 de novo center openings
- Assumes M&A spend of ~\$40M, inclusive of up to \$20M in earnouts from prior years' acquisitions
- Assumes no further COVID-related impacts or changes in the labor market environment

Note: Center Margin and Adjusted EBITDA anticipated for fourth quarter of 2023 and full year 2023 are calculated in a manner consistent with the historical presentation of these measures in the Appendix to this presentation. Reconciliation for the forward- looking fourth quarter of 2023 and full year 2023 Center Margin and Adjusted EBITDA guidance is not being provided, as LifeStance does not currently have sufficient data to accurately estimate the variables and individual adjustments for such reconciliation. LifeStance management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results.



Appendix



Quarterly Statements of Operations and Comprehensive Loss

		2023		2022				
(\$M)	Q3	Q2	Q1	Q4	Q3	Q2	Q1	
Total revenue	\$262.9	\$259.6	\$252.6	\$229.4	\$217.6	\$209.5	\$203.1	
Operating expenses								
Center costs, excluding depreciation and amortization	186.7	186.6	183.0	166.7	157.3	149.7	148.9	
General and administrative expenses	130.9	101.9	84.6	89.8	81.2	103.6	103.4	
Depreciation and amortization	19.6	19.5	19.1	18.9	17.9	16.7	15.7	
Loss from operations	(74.4)	(48.4)	(34.1)	(46.0)	(38.8)	(60.5)	(64.9)	
Other income (expense)								
Gain (loss) on remeasurement of contingent consideration	1.9	1.5	1.0	(2.2)	1.2	(0.2)	(0.4)	
Transaction costs	_	(0.0)	(0.1)	(0.2)	(0.2)	(0.0)	(0.3)	
Interest expense, net	(5.5)	(5.1)	(5.1)	(5.2)	(4.2)	(7.1)	(3.4)	
Other expense	(0.0)	(0.0)	(0.0)	(0.1)	(0.1)	_	-	
Total other expense	(3.6)	(3.6)	(4.2)	(7.7)	(3.4)	(7.3)	(4.2)	
Loss before income taxes	(78.0)	(52.0)	(38.3)	(53.7)	(42.2)	(67.8)	(69.0	
Income tax benefit (provision)	16.4	6.5	4.0	7.1	4.4	(0.9)	6.7	
Net loss	(\$61.6)	(\$45.5)	(\$34.2)	(\$46.7)	(\$37.9)	(\$68.7)	(\$62.3)	
Other comprehensive income (loss)								
Unrealized gains (losses) on cash flow hedge, net of tax	0.2	2.1	(1.3)	0.1	3.2	_	_	
Comprehensive loss	(\$61.4)	(\$43.3)	(\$35.5)	(\$46.6)	(\$34.7)	(\$68.7)	(\$62.3)	

Subtotals in the schedule above may not foot due to rounding. Amounts are unaudited



Quarterly GAAP to Non-GAAP Reconciliations – Center Margin

		2023					
(\$M)	Q3	Q2	Q1	Q4	Q3	Q2	Q1
Loss from operations	(\$74.4)	(\$48.4)	(\$34.1)	(\$46.0)	(\$38.8)	(\$60.5)	(\$64.9)
Adjusted for:							
Depreciation and amortization	19.6	19.5	19.1	18.9	17.9	16.7	15.7
General and administrative expenses (1)	130.9	101.9	84.6	89.8	81.2	103.6	103.4
Center Margin	\$76.2	\$73.0	\$69.6	\$62.7	\$60.3	\$59.8	\$54.2

Subtotals in the schedule above may not foot due to rounding. Amounts are unaudited.

⁽¹⁾ Represents salaries, wages and employee benefits for our executive leadership, finance, human resources, marketing, billing and credentialing support and technology infrastructure and stock-based compensation for all employees.



Quarterly GAAP to Non-GAAP Reconciliations – Adjusted EBITDA

		2023				2022			
(\$M)	Q3	Q2	Q1	Q4	Q3	Q2	Q1		
Net loss	(\$61.6)	(\$45.5)	(\$34.2)	(\$46.7)	(\$37.9)	(\$68.7)	(\$62.3)		
Adjusted for:									
Interest expense, net	5.5	5.1	5.1	5.2	4.2	7.1	3.4		
Depreciation and amortization	19.6	19.5	19.1	18.9	17.9	16.7	15.7		
Income tax (benefit) provision	(16.4)	(6.5)	(4.0)	(7.1)	(4.4)	0.9	(6.7)		
(Gain) loss on remeasurement of contingent consideration	(1.9)	(1.5)	(1.0)	2.2	(1.2)	0.2	0.4		
Stock-based compensation	21.5	33.1	23.9	35.2	34.9	57.5	59.9		
Loss on disposal of assets	0.0	0.0	0.0	0.1	0.1	_	_		
Transaction costs (1)	_	0.0	0.1	0.2	0.2	0.0	0.3		
Executive transition costs	0.1	0.4	0.2	0.8	0.5	_	_		
Litigation costs (2)	45.4	3.4	0.4	0.7	0.1	_	_		
Strategic initiatives (3)	0.8	2.0	0.4	_	_	_	_		
Real estate optimization and restructuring charges (4)	1.3	3.7	_	_	_	_	_		
Other expenses (5)	0.2	0.3	0.3	0.6	0.9	0.9	1.8		
Adjusted EBITDA	\$14.6	\$14.1	\$10.1	\$10.2	\$15.4	\$14.6	\$12.5		

(1) Primarily includes capital markets advisory, consulting, accounting and legal expenses related to our acquisitions.
(2) Litigation costs include only those costs which are considered non-recurring and outside of the ordinary course of business based on the following considerations, which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be be rought within two years, (ii) the complexity of the case, (e.g., complex, class action litigation, (iii) the nature of the remedy(ies) sought, including the size of any monetary damages sought, (iv) the counterparty involved, and (v) our overall litigation strategy.

During the three and nine months ended September 30, 2023, litigation costs included cash expenses related to three distinct litigation matters, including (x) a securities class action litigation, (y) a privacy class action litigation and (z) a compensation model class action litigation and (z) a compensation model class action litigation.

During the three and nine months ended September 30, 2013, litigation costs included casn expenses related to to multi-phase related to a multi-phase system upgrade in connection with our recent and included casn expenses and (iii) a scalable electronic health resources system. Strategic initiatives represents costs, such as third-party consulting costs and one-time costs, that are not part of our ongoing operations related to these enterprise-wide systems. We considered the frequency and scale of this multi-part enterprise upgrade when determining that the expenses were not normal, recurring operating expenses. All of the expenses were not normal, recurring operating expenses, and exit and disposal costs related to to use, certain gains and observabled to our real estate on the expenses and non-cash charges related to our real estate optimization initiative to consolidate our physical footprint. As the decision to close these centers was part of a significant strategic project driven by a historic shift in behavior, the magnitude of center closures has been all sepected to be greater than what would be expected as part of ordinary business operations and not constitute normal expensions. (S) Primarily includes costs incurred to consummate or integrate acquired centers, certain of which are wholly-owned and certain of which are affiliated practices, in addition to the compensation paid to former owners of acquired centers and related expenses and comprehensive loss. Former owner feets is a component of center cost, excluding depreciation and amortization included in our unaudited consolidated statements operations and comprehensive loss.



Non-GAAP Financial Metrics

		2023			2022			
(\$M)	Q3	Q2	Q1	Q4	Q3	Q2	Q1	
Key Metrics								
Clinicians	6,418	6,132	5,961	5,631	5,431	5,226	4,98	
Total Revenue	\$262.9	\$259.6	\$252.6	\$229.4	\$217.6	\$209.5	\$203.	
Center costs, excluding depreciation and amortization	186.7	186.6	183.0	166.7	157.3	149.7	148.	
Center Margin (Non-GAAP)	\$76.2	\$73.0	\$69.6	\$62.7	\$60.3	\$59.8	\$54.	
% Margin	29.0%	28.1%	27.6%	27.3%	27.7%	28.5%	26.79	
General and administrative expenses	130.9	101.9	84.6	89.8	81.2	103.6	103	
Depreciation and amortization	19.6	19.5	19.1	18.9	17.9	16.7	15	
Loss from operations	(74.4)	(48.4)	(34.1)	(46.0)	(38.8)	(60.5)	(64.9	
Other income (expense)								
Other income (expense)	12.8	2.9	(0.1)	(0.6)	1.0	(8.3)	2.	
Net loss	(\$61.6)	(\$45.5)	(\$34.2)	(\$46.7)	(\$37.9)	(\$68.7)	(\$62.3	
Unrealized gains (losses) on cash flow hedge, net of tax Comprehensive loss	0.2 (\$61.4)	(\$43.3)	(1.3) (\$35.5)	0.1 (\$46.6)	3.2 (\$34.7)	(\$68.7)	(\$62.3	
Adit of department and	,							
Adjusted EBITDA build Net loss	(61.6)	(45.5)	(34.2)	(46.7)	(37.9)	(68.7)	(62.:	
Interest expense, net	(61.6)	(45.5)	(34.2)	5.2	4.2	7.1	(62.:	
Depreciation and amortization	19.6	19.5	19.1	18.9	17.9	16.7	15	
Income tax benefit (provision)	(16.4)	(6.5)	(4.0)	(7.1)	(4.4)	0.9	(6.	
(Gain) loss on remeasurement of contingent consideration	(1.9)	(1.5)	(1.0)	2.2	(1.2)	0.2	0	
Stock-based compensation	21.5	33.1	23.9	35.2	34.9	57.5	59	
Loss on disposal of assets	0.0	0.0	0.0	0.1	0.1	_		
Transaction costs	_	0.0	0.1	0.2	0.2	0.0	0	
Executive transition costs	0.1	0.4	0.2	0.8	0.5	_		
Litigation costs	45.4	3.4	0.4	0.7	0.1	_		
Strategic initiatives	0.8	2.0	0.4	_	_	_		
Real estate optimization and restructuring charges	1.3	3.7	_	_	_	_		
Other expenses	0.2	0.3	0.3	0.6	0.9	0.9	1	
Adjusted EBITDA (Non-GAAP)	\$14.6	\$14.1	\$10.1	\$10.2	\$15.4	\$14.6	\$12.	
% Margin	5.6%	5.4%	4.0%	4.4%	7.1%	7.0%	6	

Subtotals in the schedule above may not foot due to rounding. Amounts are unaudited

1,



Quarterly Balance Sheets

		2023			2022			
(\$M)	Q3	Q2	Q1	Q4	Q3	Q2	Q1	
Current assets								
Cash and cash equivalents	42.6	79.6	68.3	108.6	90.3	96.7	114.0	
Patient accounts receivable, net	149.7	121.8	118.4	100.9	113.3	99.7	95.0	
Prepaid expenses and other current assets	71.9	36.5	25.8	23.7	49.0	47.9	54.3	
Total current assets	264.3	237.9	212.5	233.2	252.6	244.3	263.3	
Property and equipment, net	190.1	193.1	193.5	194.2	193.4	190.7	170.9	
Right-of-use assets	180.7	191.4	196.2	199.4	-	-	_	
Intangible assets, net	233.6	243.8	254.0	263.3	272.5	282.1	291.2	
Goodwill	1,293.4	1,293.5	1,293.6	1,272.9	1,249.8	1,243.7	1,229.3	
Other noncurrent assets	13.0	11.2	8.8	10.8	11.4	7.9	3.7	
Total noncurrent assets	1,910.8	1,933.0	1,946.1	1,940.6	1,727.1	1,724.4	1,695.1	
Total assets	\$2,175.1	\$2,170.9	\$2,158.6	\$2,173.9	\$1,979.7	\$1,968.7	\$1,958.4	
Accounts payable	10.4	8.0	7.7	12.3	7.9	12.9	15.1	
Accrued payroll expenses	83.6	81.1	83.7	75.7	61.6	61.2	73.2	
Other accrued expenses	91.0	34.3	32.0	30.4	29.3	26.2	21.8	
Current portion of contingent consideration	9.0	10.5	13.3	15.9	10.8	9.0	13.5	
Operating lease liabilities, current	43.6	43.4	41.6	38.8	_	_	-	
Other current liabilities	3.3	3.3	2.8	2.9	2.6	2.2	2.0	
Total current liabilities	240.9	180.9	181.1	176.0	112.3	111.5	125.6	
Long-term debt, net	248.4	248.7	224.8	225.1	212.0	203.4	177.4	
Operating lease liabilities, noncurrent	191.5	205.6	207.9	212.6	_	_	_	
Contingent consideration, net of current portion	_	_	_	_	1.5	3.7	1.3	
Deferred tax liability, net	38.4	38.3	37.6	38.7	55.4	54.3	54.3	
Other noncurrent liabilities	0.9	2.6	2.1	2.8	67.0	64.5	57.5	
Total noncurrent liabilities	479.1	495.2	472.3	479.1	335.9	325.8	290.3	
Total liabilities	\$720.0	\$676.0	\$653.4	\$655.1	\$448.2	\$437.4	\$415.9	
Common stock	3.8	3.8	3.8	3.8	3.8	3.8	3.7	
Additional paid-in capital	2,162.8	2,141.2	2,108.2	2,084.3	2,050.5	2,015.7	1,958.2	
Accumulated other comprehensive income	4.4	4.2	2.0	3.3	3.2	_	_	
Accumulated deficit	(715.9)	(654.3)	(608.8)	(572.6)	(526.0)	(488.1)	(419.4	
Total stockholders' equity	1,455.0	1,494.9	1,505.1	1,518.7	1,531.5	1,531.3	1,542.5	
Total liabilities and stockholders' equity	\$2,175.1	\$2,170.9	\$2,158.6	\$2,173.9	\$1,979.7	\$1,968.7	\$1,958.4	

Subtotals in the schedule above may not foot due to rounding. Amounts are unaudited



Statements of Cash Flows

(SM)	Nine Months Ended Q3'23	Six Months Ended Q2'23	Q1′23	Nine Months Ended Q3'22	Six Months Ended Q2'22	Q1′22
CASH FLOWS FROM OPERATING ACTIVITIES						
Net loss	(141.3)	(\$79.7)	(\$34.2)	(168.9)	(\$131.1)	(\$62.3)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:						
Depreciation and amortization	58.2	38.6	19.1		32.4	15.7
Non-cash operating lease costs	30.2	20.3	10.1		-	_
Stock-based compensation	78.5	56.9	23.9			59.9
Loss on debt extinguishment	_	_	-	01.1		_
Amortization of discount and debt issue costs	1.6	1.1	0.5	1.4	0.7	0.3
(Gain) loss on remeasurement of contingent consideration	(4.4)	(2.6)	(1.0)	(0.6)	0.6	0.4
Other, net	5.1	2.7	_	_	_	_
Loss on disposal of assets	_	_	0.0	0.1	_	_
Change in operating assets and liabilities, net of businesses acquired:						
Patient accounts receivable, net	(48.5)	(20.6)	(17.1)	(34.6)	(21.9)	(18.1)
Prepaid expenses and other current assets	(52.3)	(15.2)	(4.5)	(5.8)	(5.4)	(12.1)
Accounts payable	(3.8)	(5.4)	(5.5)	1.1	1.7	1.9
Accrued payroll expenses	7.6	5.2	7.7	(0.6)	(0.3)	12.8
Operating lease liabilities	(30.1)	(16.9)	(8.7)	_	_	_
Other accrued expenses	65.6	7.3	2.0	18.8	13.5	4.9
Net cash (used in) provided by operating activities	(\$33.7)	(\$8.3)	(\$7.9)	\$16.9	\$11.1	\$3.3
CASH FLOWS FROM INVESTING ACTIVITIES						
Purchases of property and equipment	(29.1)	(19.3)	(7.7)	(68.9)	(53.8)	(27.9)
Acquisitions of businesses, net of cash acquired	(19.8)	(19.8)	(19.8)	(40.3)	(35.1)	(22.9)
Net cash used in investing activities	(\$48.9)	(\$39.1)	(\$27.5)	(\$109.2)	(\$88.9)	(\$50.9)
CASH FLOWS FROM FINANCING ACTIVITIES						
Proceeds from long-term debt, net of discount	25.0	25.0	-	237.5		20.0
Payments of debt issue costs	(0.2)	(0.2)	-	(7.3)	(7.2)	-
Payments of long-term debt	(1.8)	(1.2)	(0.6)	(181.2)	(181.2)	(0.3)
Prepayment for debt paydown	_	_	_	(1.6)	(1.6)	_
Payments of contingent consideration	(6.4)	(5.2)	(4.3)	(12.3)	(11.1)	(5.7)
Taxes related to net share settlement of equity awards				(0.5)	(0.5)	(0.4)
Net cash provided by (used in) financing activities	\$16.6	\$18.4	(\$4.9)	\$34.6	\$26.4	\$13.5
NET DECREASE IN CASH AND CASH EQUIVALENTS	(\$66.0)	(\$29.0)	(\$40.3)	(\$57.7)	(\$51.3)	(\$34.0)
Cash and Cash Equivalents - Beginning of period	108.6	108.6	108.6	148.0	148.0	148.0
CASH AND CASH EQUIVALENTS – END OF PERIOD	\$42.6	\$79.6	\$68.3	\$90.3	\$96.7	\$114.0

Subtotals in the schedule above may not foot due to rounding. Amounts are unaudited

1:



Quarterly GAAP to Non-GAAP Reconciliations – Free Cash Flow (FCF)

		2023			2022		
(\$M)	Q3	Q2	Q1	Q4	Q3	Q2	Q1
Net cash (used in) provided by operating activities	(\$25.4)	(\$0.4)	(\$7.9)	\$36.0	\$5.7	\$7.8	\$3.3
Purchases of property and equipment	(\$9.8)	(\$11.6)	(\$7.7)	(\$10.4)	(\$15.1)	(\$25.9)	(\$27.9)
Free Cash Flow	(\$35.2)	(\$12.0)	(\$15.6)	\$25.6	(\$9.4)	(\$18.1)	(\$24.6)

We define FCF, a non-GAAP performance measure, as net cash (used in) provided by operating activities less purchases of property and equipment. We believe that FCF is a useful indicator of liquidity that provides information to management and investors about the amount of cash generated from our operations that, after investments in property and equipment, can be used for future growth. FCF is presented for supplemental informational purposes only and has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of other GAAP financial measures, such as net cash (used in) provided by operating activities. It is important to note that other companies, including companies in our industry, may not use this metric, may calculate metrics differently, or may use other financial measures to evaluate their liquidity, all of which could reduce the usefulness of this non-GAAP metrics as a comparative measure.

The above table presents a reconciliation of net cash (used in) provided by operating activities to FCF, the most directly comparable financial measure calculated in accordance with GAAP. Amounts are unaudited.



Quarterly Visits and Total Revenue Per Visit

		2023			2022			
	Q3	Q2	Q1	Q4	Q3	Q2	Q1	
Total Revenue (\$M)	\$262.9	\$259.6	\$252.6	\$229.4	\$217.6	\$209.5	\$203.1	
Total Visits (000s)	1,714	1,705	1,665	1,487	1,429	1,413	1,392	
Total Revenue Per Visit (TRPV)	\$153.4	\$152.3	\$151.7	\$154.3	\$152.3	\$148.3	\$145.9	

Amounts are unaudite